CorMedix (CRMD) announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, reaffirming his long-term commitment to the organization. In addition to his role as CEO, Mr. Todisco will also assume the role of Chairman of the Board of Directors, succeeding Myron Kaplan. Mr. Kaplan will transition into a newly created board position of Lead Independent Director.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix sees Q4 revenue $127M, consensus $127.52M
- DefenCath’s Strong Clinical and Economic Profile Underpins Buy Rating Despite Anticipated 2026 Pricing Headwinds
- CorMedix announces interim results for DefenCath
- Cormedix’s Promising Outlook: Strong Financial Performance, Strategic Acquisition, and Growth Catalysts Justify Buy Rating
- CorMedix price target raised to $18 from $17 at H.C. Wainwright